ABBOTT LABORATORIES vs Johnson & Johnson, two Drug Manufacturers stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Abbott and Johnson & Johnson are two diversified pillars of American healthcare, and the larger one runs the better income statement. J&J keeps a 22% net margin to Abbott's 14 and earns a 26% return on equity to Abbott's 12, on a similar balance sheet. Abbott is the slightly cheaper of the two, near 25 times earnings to J&J's 28, and both pay dividends in the 2.2 to 2.7% range. Abbott's edge is its device and diagnostics mix; J&J's is sheer scale and a pharma pipeline, and right now the scale is winning on the numbers.
Comparison updated 2026-06-11.
| Metric | ABT | JNJ |
|---|---|---|
| Price | $93.93 | $256.93 |
| Market cap | $164.1B | $628.2B |
| Sector | Drug Manufacturers | Drug Manufacturers |
| Stage | Mature | Mature |
| Implied growth (priced in) | +9.6% | — |
| P/E | 26.3 | 29.8 |
| P/B | 3.11 | 7.74 |
| P/S | 3.64 | 6.52 |
| EV/EBITDA | 20.8 | 329.9 |
| Revenue growth | +6.6% | +7.9% |
| Gross margin | — | 66.3% |
| Operating margin | 12.1% | — |
| Net margin | 13.9% | 21.8% |
| Return on equity | 11.9% | 25.9% |
| Return on assets | 5.7% | 10.5% |
| Return on invested capital | 6.6% | — |
| FCF yield | 4.5% | 2.8% |
| Dividend yield | 2.6% | 2.0% |
| Debt / equity | 0.65 | 0.68 |
| Current ratio | 1.39 | 1.03 |
| Altman Z (solvency) | 7.16 | 4.82 |
| Piotroski F (quality) | 6 / 9 | 5 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.